Seagen Inc

NASDAQ:SGEN  
127.67
-5.39 (-4.05%)
Products, Regulatory

Seagen Announces Preliminary Results From Phase 2 Clinical Trial Of Adcetris® (Brentuximab Vedotin) In Novel Combination Of Agents For Patients With Advanced Stage Classical Hodgkin Lymphoma

Published: 12/12/2021 23:40 GMT
Seagen Inc (SGEN) - Seagen Announces Preliminary Results From Phase 2 Clinical Trial of Adcetris® (brentuximab Vedotin) in Novel Combination of Agents for Patients With Advanced Stage Classical Hodgkin Lymphoma.
Frontline Treatment With Adcetris in Combination With Nivolumab, Doxorubicin & Dacarbazine Shows Complete Response Rate of 88%.
Preliminary Results Demonstrated a Complete Response Rate of 88 Percent and Overall Response Rate of 93 Percent.